Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
19.02
-0.25 (-1.30%)
Dec 20, 2024, 4:00 PM EST - Market closed
Cartesian Therapeutics Employees
As of December 31, 2023, Cartesian Therapeutics had 38 total employees, including 37 full-time and 1 part-time employees.
Employees
38
Change
n/a
Growth
n/a
Revenue / Employee
$1,261,526
Profits / Employee
-$7,431,026
Market Cap
489.30M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Auna S.A. | 14,958 |
| Talkspace | 472 |
| Sangamo Therapeutics | 405 |
| Xeris Biopharma Holdings | 377 |
| EyePoint Pharmaceuticals | 121 |
| Theravance Biopharma | 99 |
| Semler Scientific | 92 |
| PureTech Health | 90 |
RNAC News
- 3 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 18 days ago - Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial - GlobeNewsWire
- 4 weeks ago - Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics: Uncertainty Remains - Seeking Alpha
- 2 months ago - Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results - Seeking Alpha
- 3 months ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 3 months ago - Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 - GlobeNewsWire